NAM
FATE icon

NorthCrest Asset Manangement’s Fate Therapeutics FATE Stock Holding History

NorthCrest Asset Manangement’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2K Buy
+10,359
New +$19.2K ﹤0.01% 915

Other funds holding FATE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
WP
Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
HNB
Hilltop National Bank Casper, Wyoming $468M AUM 36.09% 1-Year Est. Return

NorthCrest Asset Manangement's FATE Position: Q2 2026 in Review

NorthCrest Asset Manangement opened a new position in Fate Therapeutics (FATE) in Q2 2026: 10,359 shares worth $32.2K. The stake represents ﹤0.01% of the portfolio and ranks #915 among its holdings.

8 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • NorthCrest Asset Manangement held 10,359 shares of Fate Therapeutics worth $32.2K as of Q2 2026.
  • Fate Therapeutics was a new NorthCrest Asset Manangement position in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #915 holding.
  • 8 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.